Abbott Laboratories (NYSE:ABT) – Research analysts at Leerink Swann upped their Q4 2018 earnings per share estimates for shares of Abbott Laboratories in a research note issued on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the healthcare product maker will earn $0.82 per share for the quarter, up from their previous estimate of $0.81. Leerink Swann currently has a “Market Perform” rating and a $68.00 target price on the stock. Leerink Swann also issued estimates for Abbott Laboratories’ Q1 2019 earnings at $0.64 EPS and FY2021 earnings at $3.96 EPS.

How to Become a New Pot Stock Millionaire

A number of other brokerages also recently commented on ABT. ValuEngine downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. BTIG Research downgraded shares of Abbott Laboratories from a “buy” rating to a “neutral” rating in a research report on Monday, January 22nd. They noted that the move was a valuation call. Barclays reaffirmed a “buy” rating and set a $66.00 price objective on shares of Abbott Laboratories in a research report on Monday, January 8th. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $67.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Finally, JPMorgan Chase & Co. raised shares of Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 price objective on the stock in a research report on Tuesday, January 2nd. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Abbott Laboratories has an average rating of “Buy” and an average price target of $65.47.

Abbott Laboratories stock traded down $0.85 during trading on Thursday, hitting $61.57. 1,550,174 shares of the stock traded hands, compared to its average volume of 7,183,751. The stock has a market capitalization of $109,407.83, a P/E ratio of 237.43, a P/E/G ratio of 1.86 and a beta of 1.52. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.86 and a current ratio of 2.26. Abbott Laboratories has a 1-year low of $42.31 and a 1-year high of $64.60.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. The business had revenue of $7.59 billion for the quarter, compared to the consensus estimate of $7.38 billion. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.88%. The firm’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same period last year, the firm posted $0.65 earnings per share.

Institutional investors have recently modified their holdings of the company. Rowland & Co. Investment Counsel ADV bought a new position in Abbott Laboratories during the fourth quarter worth $102,000. Icon Wealth Partners LLC bought a new position in Abbott Laboratories during the fourth quarter worth $102,000. SWS Partners bought a new position in Abbott Laboratories during the fourth quarter worth $104,000. Heritage Trust Co increased its position in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after acquiring an additional 200 shares during the period. Finally, Tributary Capital Management LLC bought a new position in Abbott Laboratories during the third quarter worth $106,000. Institutional investors and hedge funds own 72.35% of the company’s stock.

In other news, insider Jared Watkin sold 3,000 shares of the business’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $61.19, for a total value of $183,570.00. Following the completion of the sale, the insider now directly owns 68,215 shares in the company, valued at $4,174,075.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Roger Bird sold 8,262 shares of the business’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $62.75, for a total transaction of $518,440.50. Following the completion of the sale, the insider now owns 58,574 shares of the company’s stock, valued at $3,675,518.50. The disclosure for this sale can be found here. Insiders sold 124,261 shares of company stock valued at $7,559,987 over the last quarter. Corporate insiders own 0.76% of the company’s stock.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date is Thursday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 430.79%.

ILLEGAL ACTIVITY NOTICE: “Leerink Swann Comments on Abbott Laboratories’ Q4 2018 Earnings (ABT)” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/leerink-swann-comments-on-abbott-laboratories-q4-2018-earnings-abt/1956629.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.